Search hospitals > Indiana > Indianapolis
Indiana University School of Medicine
Claim this profileIndianapolis, Indiana 46202
Global Leader in Alzheimer's Disease
Global Leader in Diabetes
Conducts research for Dementia
Conducts research for Cancer
Conducts research for Fibrosis
232 reported clinical trials
27 medical researchers
Summary
Indiana University School of Medicine is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Alzheimer's Disease, Diabetes, Dementia, Cancer, Fibrosis and other specialties. Indiana University School of Medicine is involved with conducting 232 clinical trials across 363 conditions. There are 27 research doctors associated with this hospital, such as Monika Fischer, Linda DiMeglio, MD, Raj Vuppalanchi, MD, and Jared Brosch.Area of expertise
1Alzheimer's Disease
Global LeaderPSEN2 positive
PSEN1 positive
APP positive
2Diabetes
Global LeaderTop PIs
Monika FischerIndiana University2 years of reported clinical research
Studies Crohn's Disease
Studies Ulcerative Colitis
12 reported clinical trials
14 drugs studied
Linda DiMeglio, MDIndiana University - Riley Hospital for Children2 years of reported clinical research
Studies Type 1 Diabetes
Studies Diabetes
10 reported clinical trials
18 drugs studied
Raj Vuppalanchi, MDIndiana University School of Medicine1 year of reported clinical research
Studies Non-alcoholic Fatty Liver Disease
Studies Fatty Liver Disease
9 reported clinical trials
9 drugs studied
Jared BroschIndiana University School of Medicine3 years of reported clinical research
Studies Alzheimer's Disease
Studies Dementia
9 reported clinical trials
17 drugs studied
Clinical Trials running at Indiana University School of Medicine
Alzheimer's Disease
Ulcerative Colitis
Pulmonary Hypertension
Type 1 Diabetes
Diabetes
Oligodendroglioma
Neurofibromatosis
Ulcer
Inflammatory Bowel Disease
Dementia
AVP-786
for Agitation in Alzheimer's Disease
This trial is testing a medication called AVP-786 on individuals who have taken part in previous studies. The goal is to see if this medication can help with their conditions over time.
Recruiting2 awards Phase 37 criteria
Lecanemab
for Alzheimer's Disease
This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to external controls, if amyloid plaque as measured by amyloid PET can be fully removed in DIAD, and the effects of amyloid removal on biomarkers of disease progression.
Recruiting2 awards Phase 3
Aducanumab
for Alzheimer's Disease
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's disease.
Recruiting1 award Phase 31 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Indiana University School of Medicine?
Indiana University School of Medicine is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Alzheimer's Disease, Diabetes, Dementia, Cancer, Fibrosis and other specialties. Indiana University School of Medicine is involved with conducting 232 clinical trials across 363 conditions. There are 27 research doctors associated with this hospital, such as Monika Fischer, Linda DiMeglio, MD, Raj Vuppalanchi, MD, and Jared Brosch.